Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
33.28
+0.85 (2.62%)
After Hours: 35.15 +1.87 (5.62%)
Aug 27, 4:46PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 32.67 - 33.62
52 week 27.51 - 36.46
Open 32.78
Vol / Avg. 37.57M/24.08M
Mkt cap 199.71B
P/E 23.60
Div/yield 0.28/3.37
EPS 1.41
Shares 6.17B
Beta 0.74
Inst. own 73%
Oct 26, 2015
Q3 2015 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2015
Q2 2015 Pfizer Inc Earnings Call
Jul 28, 2015
Q2 2015 Pfizer Inc Earnings Release
Jun 2, 2015
Pfizer Inc Corporate Call - Oncology Business Review and ASCO Data Presentations
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 22.22% 18.39%
Operating margin 31.67% 25.66%
EBITD margin - 40.72%
Return on average assets 6.57% 5.34%
Return on average equity 15.70% 12.32%
Employees 78,300 -
CDP Score - 92 B

Address

235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 57
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 56
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 54
Bio & Compensation  - Reuters
John D Young Group President - Global Established Pharma Business
Age: 50
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 53
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 59
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters